Exclusive Summary

• Sodium Valproate Concentrated Solution for Injection is a potent antiepileptic drug for emergency and substitute therapy, with most global patents expired, indicating low market entry barriers.
• Epilepsy has a large and stable global patient population, especially in developing countries, where sodium valproate injection plays an indispensable role.
• The product has passed China's Consistency Evaluation and is categorized as Class B in national medical insurance, signifying recognized quality and efficacy, laying a solid foundation for international registration.
• It offers a cost advantage over the originator drug, particularly suitable for markets with limited payment capabilities, effectively improving drug accessibility.

Asset Materials

Contact Us for Full Materials